AI assistant
Cellectar Biosciences, Inc. — Director's Dealing 2016
Jan 4, 2016
35021_dirs_2016-01-04_271f27f0-d0ab-4db5-8f31-e10e1770d4b1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2015-12-30
Reporting Person: AWM Investment Company, Inc. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-12-30 | Common Stock | S | 64747 | $0.6873 | Disposed | 35253 | Indirect |
| 2015-12-31 | Common Stock | S | 35253 | $0.6955 | Disposed | 0 | Indirect |
Footnotes
F1: This is a weighted average price.
F2: AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (SSFQP), Special Situations Cayman Fund, L.P. (CAYMAN) and Special Situations Life Sciences Fund, L.P. (SSLS and together with SSFQP and CAYMAN, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 0 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 0 Shares held by CAYMAN and 0 Shares held by SSLS.
F3: Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM.
The reporting person disclaims beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not
be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the
Securities Exchange Act of 1934, as amended, or for any other purpose.